Novocure (NVCR) Announces Q4 Operating Statistics, Preliminary Net Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- S&P 500, Nasdaq edge higher as chips recover; megacap earnings in focus
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update
January 7, 2019 4:05 PM ESTFull year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017
Fourth quarter and full year 2018 financial results to be reported Thursday, Feb. 28, 2019
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2018. Novocure plans to discuss these results with investors at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also highlighted anticipated clinical and regulatory milestones, announced national reimbursement in Sweden and... More
